Wiktor Kuliczkowski

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/614512/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. European Heart Journal, 2008, 30, 426-435.	2.2	192
2	Anticoagulant and anti-platelet activity of polyphenolic-polysaccharide preparation isolated from the medicinal plant Erigeron canadensis L Thrombosis Research, 2011, 127, 328-340.	1.7	93
3	Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease. Thrombosis and Haemostasis, 2008, 100, 76-82.	3.4	84
4	Association of platelet responsiveness with clopidogrel metabolism: Role of compliance in the assessment of "resistanceâ€. American Heart Journal, 2009, 158, 925-932.	2.7	64
5	Plasma Adiponectin Concentration in Relation to Severity of Coronary Atherosclerosis and Cardiovascular Risk Factors in Middle-Aged Men. Endocrine, 2004, 25, 215-222.	2.2	32
6	Inter-patient variability and impact of proton pump inhibitors on platelet reactivity after prasugrel. Thrombosis and Haemostasis, 2012, 107, 338-345.	3.4	29
7	Plasma Triglycerides as Predictors of Platelet Responsiveness to Aspirin in Patients after First Ischemic Stroke. Cerebrovascular Diseases, 2008, 26, 272-276.	1.7	21
8	Gastrointestinal Adverse Events after Dual Antiplatelet Therapy: Clopidogrel Is Safer than Ticagrelor, but Prasugrel Data Are Lacking or Inconclusive. Cardiology, 2013, 126, 35-40.	1.4	21
9	The in vitro effects of niacin on platelet biomarkers in human volunteers. Thrombosis and Haemostasis, 2010, 104, 311-317.	3.4	19
10	Platelet inhibition with standard vs. lower maintenance dose of ticagrelor early after myocardial infarction (ELECTRA): a randomized, open-label, active-controlled pharmacodynamic and pharmacokinetic study. European Heart Journal - Cardiovascular Pharmacotherapy, 2019, 5, 139-148.	3.0	18
11	Rationale and Design of the Effectiveness of LowEr maintenanCe dose of TicagRelor early After myocardial infarction (ELECTRA) pilot study. European Heart Journal - Cardiovascular Pharmacotherapy, 2018, 4, 152-157.	3.0	16
12	Endothelial Progenitor Cells and Left Ventricle Function in Patients With Acute Myocardial Infarction: Potential Therapeutic Considertions. American Journal of Therapeutics, 2012, 19, 44-50.	0.9	14
13	Aspirin failure course during exercise and its connection with soluble CD40L. Thrombosis Research, 2007, 119, 679-686.	1.7	13
14	Effect of Glycemic Control on Response to Antiplatelet Therapy in Patients With Diabetes Mellitus and ST-Segment Elevation Myocardial Infarction. American Journal of Cardiology, 2012, 110, 331-336.	1.6	13
15	MMP-2, MMP-9, and TIMP-4 and Response to Aspirin in Diabetic and Nondiabetic Patients with Stable Coronary Artery Disease: A Pilot Study. BioMed Research International, 2017, 2017, 1-12.	1.9	13
16	Daily risk of adverse outcomes in patients undergoing complex lesions revascularization: A subgroup analysis from the RAIN-CARDIOGROUP VII study (veRy thin stents for patients with left mAIn or) Tj ETQq0 0 0 rg	gBT 10 verlo	ock 113 0 Tf 50 1
17	Predicting Bleeding Risk by Platelet Function Testing in Patients Undergoing Heart Surgery. Clinical Cardiology, 2015, 38, 679-683.	1.8	11

Aptamers: the emerging class of future anticoagulation for vascular disease. Expert Review of Cardiovascular Therapy, 2010, 8, 503-507.

1.5 9

#	Article	IF	CITATIONS
19	Sealing of Coronary Perforations With a Second-Generation Covered Stent Graft - Results From the PAST-PERF Registry. Cardiovascular Revascularization Medicine, 2021, 25, 20-26.	0.8	9
20	Long-Term Outcomes Following Drug-Eluting Balloons Versus Thin-Strut Drug-Eluting Stents for Treatment of In-Stent Restenosis (DEB-Dragon-Registry). Circulation: Cardiovascular Interventions, 2021, 14, e010868.	3.9	9
21	Aspirin resistance in ischaemic heart disease. Kardiologia Polska, 2005, 62, 14-25.	0.6	9
22	The Risk for Syncope and Presyncope During Surgery in Surgeons and Nurses. PACE - Pacing and Clinical Electrophysiology, 2011, 34, 1486-1491.	1.2	8
23	Matrix metalloproteinases and the activity of their tissue inhibitors in patients with ST-elevation myocardial infarction treated with primary angioplasty. Kardiologia Polska, 2013, 71, 453-463.	0.6	8
24	Aspirin â€~Resistance': Impact on No-Reflow, Platelet and Inflammatory Biomarkers in Diabetics after ST-Segment Elevation Myocardial Infarction. Cardiology, 2015, 131, 41-50.	1.4	8
25	Incidence and causes of new-onset dyspnea in 3,719 patients treated with clopidogrel and aspirin combination after coronary stenting. Thrombosis and Haemostasis, 2008, 100, 314-318.	3.4	7
26	Excessive Long-Term Platelet Inhibition With Prasugrel or Ticagrelor and Risk of Infection. American Journal of Therapeutics, 2015, 22, e22-e27.	0.9	7
27	Sex steroids concentrations in relation to bone mineral density in men with coronary atherosclerosis. Maturitas, 2006, 55, 142-149.	2.4	6
28	Does Arterial Hypertension Affect Plasma Levels of Matrix Metalloproteinases and Their Tissue Inhibitors in Patients with Stable Coronary Artery Disease? A Preliminary Study. Cardiology Research and Practice, 2019, 2019, 1-8.	1.1	6
29	Relation Between Heavy Metals and Left Ventricular Diastolic Function in Patients with Coronary Artery Disease. Toxicology Mechanisms and Methods, 2004, 14, 177-182.	2.7	5
30	The Choice of Surgical Specialization by Medical Students and Their Syncopal History. PLoS ONE, 2013, 8, e55236.	2.5	5
31	Thrombin Generation and Platelet Reactivity at Hospital Discharge and 6-Month Outcome after the Acute Coronary Syndrome in Diabetic and Nondiabetic Patients. Cardiology, 2014, 128, 25-33.	1.4	5
32	Fatal Sepsis and Systemic Inflammatory Response Syndrome After Off-Label Prasugrel. American Journal of Therapeutics, 2014, 21, e229-e233.	0.9	5
33	Response to Dual Antiplatelet Therapy Does Not Impact Bleeding Risks in Patients Undergoing Oral Surgery after Acute Coronary Syndromes. Cardiology, 2015, 132, 119-123.	1.4	5
34	Relationship between high on aspirin platelet reactivity and oxidative stress in coronary artery by-pass grafted patients. Blood Coagulation and Fibrinolysis, 2016, 27, 151-155.	1.0	5
35	Systolic stretching of the ascending aorta. Archives of Medical Science, 2021, 17, 25-30.	0.9	5
36	Anti-aggregation therapy in patients with acute coronary syndrome — recommendations for medical emergency teams. Experts' standpoint. Kardiologia Polska, 2017, 75, 399-408.	0.6	5

#	Article	IF	CITATIONS
37	Effects of platelet and inflammatory system activation on outcomes in diabetic patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Kardiologia Polska, 2011, 69, 531-7.	0.6	5
38	Mechanical circulatory support. An expert opinion of the Association of Intensive Cardiac Care and the Association of Cardiovascular Interventions of the Polish Cardiac Society. Kardiologia Polska, 2021, 79, 1399-1410.	0.6	5
39	Trimethylamine N-oxide in cardiovascular disease. Advances in Clinical and Experimental Medicine, 2022, 31, 913-925.	1.4	5
40	Low platelet activity predicts 30 days mortality in patients undergoing heart surgery. Blood Coagulation and Fibrinolysis, 2016, 27, 199-204.	1.0	4
41	Use of vascular closure devices for endovascular interventions requiring a direct puncture of PETE grafts. Vasa - European Journal of Vascular Medicine, 2018, 47, 119-124.	1.4	4
42	Platelet polyphosphate level is elevated in patients with chronic primary thrombocytopenia: A preliminary study. Advances in Clinical and Experimental Medicine, 2020, 29, 1051-1056.	1.4	4
43	Distribution of polymorphisms in the CYP2C19 and ABCB1 genes among patients with acute coronary syndrome in Lower Silesian population. Advances in Clinical and Experimental Medicine, 2019, 28, 1621-1626.	1.4	3
44	Response to clopidogrel therapy in patients after PCI changes over time as evidenced by different platelet function tests. Polish Archives of Internal Medicine, 2016, 126, 653-661.	0.4	3
45	Resistance to oral antiplatelet drugs–a Position Paper of the Working Group on antiplatelet drug resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society. Kardiologia Polska, 2008, 66, 470-6, 480-5.	0.6	3
46	Diurnal Variability of Platelet Aggregation in Patients with Myocardial Infarction Treated with Prasugrel and Ticagrelor. Journal of Clinical Medicine, 2022, 11, 1124.	2.4	3
47	Pre-hospital treatment of patients with acute coronary syndrome: Recommendations for medical emergency teams. Expert position update 2022. Cardiology Journal, 2022, 29, 540-552.	1.2	3
48	Activated Hemostatic Biomarkers in Patients with Implanted Left Ventricle Assist Devices: Are Heparin and/or Clopidogrel Justified?. Cardiology, 2015, 131, 172-176.	1.4	2
49	No-reflow and platelet reactivity in diabetic patients with ST-segment elevation myocardial infarction: is there a link?. Postepy W Kardiologii Interwencyjnej, 2017, 4, 326-330.	0.2	2
50	Antiplatelets in acute coronary syndrome in Poland – from guidelines to clinical practice. Postepy W Kardiologii Interwencyjnej, 2021, 17, 141-154.	0.2	2
51	Intra-aneurysm sac pressure measurement using a thin pressure wire during endovascular aneurysm repair. Advances in Clinical and Experimental Medicine, 2021, 30, 309-313.	1.4	2
52	Platelet Reactivity and Response to Aspirin and Clopidogrel in Patients with Platelet Count Disorders. Cardiology Research and Practice, 2021, 2021, 1-7.	1.1	1
53	Management of bleeding in patients hospitalized in the intensive cardiac care unit: expert opinion of the Association of Intensive Cardiac Care and Section of Cardiovascular Pharmacotherapy of the Polish Cardiac Society in cooperation with specialists in other fields of medicine. Kardiologia Polska, 2019. 77, 1206-1229.	0.6	1
54	YKL-40 as a predictor of mortality after acute coronary syndrome. Polish Archives of Internal Medicine, 2020, 130, 343-345.	0.4	1

WIKTOR KULICZKOWSKI

#	Article	IF	CITATIONS
55	latrogenic circumflex coronary artery injury after mitral valve replacement. Postepy W Kardiologii Interwencyjnej, 2021, 17, 315-316.	0.2	1
56	Intravascular lithotripsy for ostial left main coronary artery disease. Kardiologia Polska, 2022, 80, 489-490.	0.6	1
57	Genetic testing in antiplatelet therapy – not effective for perioperative bleeding. Postepy W Kardiologii Interwencyjnej, 2017, 3, 187-188.	0.2	0
58	Bleeding events in Polish cardiology wards: the results of a 2-week survey. Kardiologia Polska, 2021, 79, 327-330.	0.6	0
59	Fractional flow reserve-guided treatment in coronary artery disease: Clinical practice. Advances in Clinical and Experimental Medicine, 2021, 30, 0-0.	1.4	0
60	Recurrent pulmonary embolism in a patient after COVID-19 treated with percutaneous and surgical approach. Kardiologia Polska, 2021, 79, 1042-1043.	0.6	0
61	Anti-aggregation therapy in patients with acute coronary syndrome — recommendations for medical emergency teams. Experts' standpoint. Kardiologia Polska, 2017, 75, 47-56.	0.6	0
62	Percutaneous closure of paravalvular leak (fistula) between aorta and left atrium using echocardiographic guidance. Postepy W Kardiologii Interwencyjnej, 2021, 17, 317-318.	0.2	0
63	Response to antiplatelet therapy in patients undergoing invasive treatment due to acute coronary syndrome complicated by cardiogenic shock. Postepy W Kardiologii Interwencyjnej, 2020, 16, 418-421.	0.2	0
64	Percutaneous occlusion of large aneurysmal right coronary artery saphenous vein bypass graft. Postepy W Kardiologii Interwencyjnej, 2021, 17, 313-314.	0.2	0
65	Attitudes of members of the Wroclaw Division of the Polish Cardiac Society to the European Society of Cardiology Guidelines: Survey study. Kardiologia Polska, 2022, 80, 76-79.	0.6	0
66	Citrulline and long-term mortality in patients with cardiovascular disease. Advances in Clinical and Experimental Medicine, 2022, 31, 0-0.	1.4	0